Transine Therapeutics scales with new CSO and tripling of Babraham lab space
Transine Therapeutics has hired Andy Billinton as Chief Scientific Officer as it triples its footprint at The Babraham Research Campus in Cambridge.
Transine is developing a novel class of therapeutic RNAs (SINEUPs®) capable of upregulating protein expression with a superior level of control and specificity across an unprecedented range of hard-to-treat diseases. To date these have been beyond the reach of small molecules, conventional biologics or gene therapies.
The appointment of Andy as CSO comes at a time of rapid growth for the company following its successful £13.7 million extended seed financing to accelerate its platform and portfolio development – plus a three-fold expansion of its lab and office facilities in the heart of the Cambridge life science cluster at Babraham.
Andy has more than 20-years’ experience in drug discovery and early development, driving programmes from inception, though candidate selection and into clinical development.
He joins from NodThera where he led translational efforts on multiple molecules which entered Phase 1 for indications related to innate immunity, including neuroinflammation.
Prior to this, Andy led the Neuroscience Discovery Group at MedImmune/AstraZeneca, worked with GSK targeting neurological and pain indications from idea through to Phase 2, and co-founded Transpharmation – a boutique CRO which works with academic, biotech and pharma clients to deliver bespoke in vivo model solutions.
Jan Thirkettle, CEO of Transine, said: “We are thrilled and very fortunate to have Andy join Transine. His experience, skill and passion bring innumerable benefits to the team and to our mission to develop life-changing therapeutics for serious, underserved diseases.
“Our robust seed financing, with the addition of a new investor, and recent hiring of a number of talented individuals from academia and industry has put us in a strong position to progress our pipeline.
“With Andy on board to pilot our next phase of scientific progression and the fantastic facilities we now have; we are set to assess new opportunities to further leverage our unique SINEUP® platform.”